戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 , a lipocalin superfamily member, is a novel insulin sensitizer.
2                       SH2B1 is an endogenous insulin sensitizer.
3 ns for all causes did not differ with either insulin sensitizer.
4 rget of the thiazolidinedione (TZD) class of insulin sensitizers.
5 bolic parameters showed that R-1 and S-1 are insulin sensitizers.
6 ma-dependent effects transcend their role as insulin sensitizers.
7 etagogues, and thiazolidinediones, which are insulin sensitizers.
8 g a TZD and 4,700 (65.8%) were not receiving insulin sensitizers.
9 o PTP1B can act as both insulin mimetics and insulin sensitizers.
10  per se and are influenced by the actions of insulin sensitizers.
11 ption factors to dial out adverse effects of insulin sensitizers.
12  for drug efficacy screening, especially for insulin sensitizers.
13 ng adipose-derived factor that, unlike other insulin sensitizers, acts directly on the insulin recept
14 olidinediones (TZDs), a widely used class of insulin sensitizers, acutely and specifically inhibit mi
15 uction of adiponectin, an adipocyte-specific insulin sensitizer and anti-inflammatory agent.
16 g of the thiazolidinedione class, acts as an insulin sensitizer and improves hyperglycemia.
17 amma (PPAR-gamma) agonist, rosiglitazone, an insulin sensitizer and mitochondrial activator, improves
18    We hypothesized that combination of a TZD insulin sensitizer and the glucagon-like peptide-1 recep
19  as thiazolidinediones (TZDs), are effective insulin sensitizers and anti-inflammatory agents, but th
20 NIDDM) and obesity, RXR agonists function as insulin sensitizers and can decrease hyperglycaemia, hyp
21                                              Insulin sensitizers and incretin mimetics are antidiabet
22 able by reduction of insulin resistance with insulin sensitizers and stringent control of hyperglycem
23 ds (thiazolidinediones (TZDs)) are important insulin sensitizers and were recently shown to indirectl
24  new class of oral antidiabetic agents, are "insulin sensitizers" and exert direct effects on the mec
25                  Adiponectin functions as an insulin sensitizer, and yet the underlying molecular mec
26 festyle modification, lipid-lowering agents, insulin sensitizers, and treatments to reverse endocrine
27                      Thiazolidinedione (TZD) insulin sensitizers are associated with weight gain, whe
28                               Clomiphene and insulin sensitizers are used alone and in combination to
29                    IGF-I is recognized as an insulin sensitizer at the liver and muscle, while recent
30 igned to determine whether they (or similar "insulin sensitizers") decrease cardiovascular events in
31     Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 di
32                                The advent of insulin sensitizers enables clinicians to target treatme
33  that ERalpha-derived peptide is a potential insulin sensitizer for the treatment of T2DM.
34  the impaired glucose-tolerant subjects with insulin sensitizers for 10 weeks, pioglitazone (but not
35 mework for developing safer, next-generation insulin sensitizers for metabolic disease therapy.
36 sm and is the molecular target of a class of insulin sensitizers, genetic variants that alter Pparg g
37                Rosiglitazone is an effective insulin-sensitizer, however associated with bone loss ma
38 re, we show that tirzepatide is an effective insulin sensitizer, improving insulin sensitivity in obe
39 sed by inflammatory signals but increased by insulin sensitizer in cultured adipocytes.
40 treatment of type 2 diabetes by acting as an insulin sensitizer in skeletal muscle.
41 t RXR-selective agonists (e.g., 3 and 4) are insulin sensitizers in rodent models of non-insulin-depe
42  compounds that serve as insulin mimetics or insulin sensitizers in skeletal muscle may be effective
43 cological PPAR-gamma ligands, widely used as insulin sensitizers in the treatment of type-2 diabetes
44 roach to gaining insight and suggest that an insulin sensitizer may alleviate ER stress associated wi
45 lly restored after the administration of the insulin sensitizer metformin.
46 ifestyle changes (weight loss and exercise), insulin sensitizers (metformin, troglitazone), angiotens
47 d to determine the effects of treatment with insulin sensitizers on lipolysis, we measured palmitate
48 istant states and is reversed by diet or the insulin sensitizer pioglitazone.
49 er 2 (SGLT2) inhibitor dapagliflozin and the insulin sensitizer pioglitazone.
50 ed with decreased insulin sensitivity and if insulin sensitizers play a role in prolonging islet graf
51 ARgamma), the molecular target of a class of insulin sensitizers, regulates adipocyte differentiation
52                                              Insulin sensitizers reverse phosphoinhibition of GIV and
53 er liver and kidney transplantation with the insulin sensitizer rosiglitazone (ROSI).
54 on in 3T3-L1 adipocytes is stimulated by the insulin sensitizer rosiglitazone and inhibited by the in
55  atherosclerosis, whereas treatment with the insulin sensitizer rosiglitazone attenuated both metabol
56                             Furthermore, the insulin sensitizer rosiglitazone caused striking changes
57                                          The insulin sensitizer rosiglitazone improved insulin-stimul
58 termined the effect of the thiazolidinedione insulin sensitizer rosiglitazone on these proteins.
59 atment of insulin-resistant animals with the insulin sensitizer rosiglitazone restores vessel wall CR
60 enhanced by prior treatment of mice with the insulin sensitizer rosiglitazone.
61 ated with the Sglt inhibitor phloridzin, the insulin-sensitizer rosiglitazone, or insulin.
62                  Rosiglitazone, a well known insulin sensitizer, stimulates adipocyte differentiation
63  adiponectin as an important adipose-derived insulin sensitizer that enhances fatty acid oxidation an
64  Our results demonstrate that MTZ acts as an insulin sensitizer that suppresses hepatic glucose produ
65         Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the nuclear recepto
66                       Thiazolidinediones are insulin sensitizers that activate the nuclear receptor P
67                Additional activators include insulin sensitizers (thiazolidinediones), insulin mimeti
68     After a prolonged fast, FGF21 acts as an insulin sensitizer to overcome the peripheral insulin re
69 t that FGF21 functions physiologically as an insulin sensitizer under conditions of acute refeeding a
70                Thiazolidinediones (TZDs) are insulin sensitizers used to treat patients with insulin
71 tin is an adipose tissue-secreted endogenous insulin sensitizer, which plays a key role as a mediator
72 These data support a new role for LRG1 as an insulin sensitizer with therapeutic potential given its
73         Rexinoids represent a novel class of insulin sensitizers with potential applications in the t
74 rn regulate SREBP processing and thus couple insulin sensitizers with the regulation of lipid homeost